120 related articles for article (PubMed ID: 10731049)
1. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.
Badary OA; Abdel-Naim AB; Khalifa AE; Hamada FM
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):339-44. PubMed ID: 10731049
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.
Badary OA; Al-Shabanah OA; Al-Gharably NM; Elmazar MM
Anticancer Drugs; 1998 Oct; 9(9):809-15. PubMed ID: 9840728
[TBL] [Abstract][Full Text] [Related]
3. Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
de Vos AI; Nooter K; Verweij J; Loos WJ; Brouwer E; de Bruijn P; Ruijgrok EJ; van der Burg ME; Stoter G; Sparreboom A
Ann Oncol; 1997 Nov; 8(11):1145-50. PubMed ID: 9426335
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
Gelderblom H; Loos WJ; Verweij J; van der Burg ME; de Jonge MJ; Brouwer E; Nooter K; Stoter G; Sparreboom A
Eur J Cancer; 2002 Jan; 38(1):205-13. PubMed ID: 11750851
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cisplatin combined with ondansetron in Ehrlich ascites carcinoma in vitro and in vivo.
Badary OA; Sharaby SM; Kenawy SA; El-Denshary EE; Hamada FM
Tumori; 2000; 86(2):153-6. PubMed ID: 10855854
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of cisplatin incorporated into polylactic acid microcapsules.
Araki H; Tani T; Kodama M
Artif Organs; 1999 Feb; 23(2):161-8. PubMed ID: 10027886
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effectiveness and toxicity of cisplatin-loaded long-circulating and pH-sensitive liposomes against Ehrlich ascitic tumor.
de Carvalho Maroni L; de Oliveira Silveira AC; Leite EA; Melo MM; de Carvalho Ribeiro AF; Cassali GD; de Souza CM; Souza-Fagundes EM; Caldas IR; Araújo MS; Martins-Filho OA; de Oliveira MC; Teixeira-Carvalho A
Exp Biol Med (Maywood); 2012 Aug; 237(8):973-84. PubMed ID: 22903135
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system.
Nishiyama N; Kato Y; Sugiyama Y; Kataoka K
Pharm Res; 2001 Jul; 18(7):1035-41. PubMed ID: 11496942
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free alternative paclitaxel formulation.
Jain SK; Utreja P; Tiwary AK; Mahajan M; Kumar N; Roy P
Curr Drug Saf; 2014; 9(2):145-55. PubMed ID: 24369111
[TBL] [Abstract][Full Text] [Related]
10. Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity.
Leite EA; Souza CM; Carvalho-Júnior AD; Coelho LG; Lana AM; Cassali GD; Oliveira MC
Int J Nanomedicine; 2012; 7():5259-69. PubMed ID: 23091378
[TBL] [Abstract][Full Text] [Related]
11. Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice.
Araújo JG; Mota Ld; Leite EA; Maroni Lde C; Wainstein AJ; Coelho LG; Savassi-Rocha PR; Pereira MT; de Carvalho AT; Cardoso VN; De Oliveira MC
Exp Biol Med (Maywood); 2011 Jul; 236(7):808-15. PubMed ID: 21685237
[TBL] [Abstract][Full Text] [Related]
12. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice.
Júnior AD; Mota LG; Nunan EA; Wainstein AJ; Wainstein AP; Leal AS; Cardoso VN; De Oliveira MC
Life Sci; 2007 Jan; 80(7):659-64. PubMed ID: 17141809
[TBL] [Abstract][Full Text] [Related]
13. The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines.
Liebmann J; Cook JA; Lipschultz C; Teague D; Fisher J; Mitchell JB
Cancer Chemother Pharmacol; 1994; 33(4):331-9. PubMed ID: 7904231
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent interaction between vinblastine and cisplatin in Ehrlich ascites tumors in mice.
Cemazar M; Auersperg M; Scancar J; Kirbis IS; Pogacnik A; Sersa G
J Pharmacol Exp Ther; 2002 Jul; 302(1):337-43. PubMed ID: 12065735
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats.
Uchino H; Matsumura Y; Negishi T; Koizumi F; Hayashi T; Honda T; Nishiyama N; Kataoka K; Naito S; Kakizoe T
Br J Cancer; 2005 Sep; 93(6):678-87. PubMed ID: 16222314
[TBL] [Abstract][Full Text] [Related]
16. Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
Vigano L; Locatelli A; Grasselli G; Gianni L
Invest New Drugs; 2001 May; 19(2):179-96. PubMed ID: 11392452
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
[TBL] [Abstract][Full Text] [Related]
18. Histological vis-a-vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on experimental animal models.
Pal S; Sadhu AS; Patra S; Mukherjea KK
J Exp Clin Cancer Res; 2008 Nov; 27(1):68. PubMed ID: 19014472
[TBL] [Abstract][Full Text] [Related]
19. Effects of paclitaxel with or without cremophor EL on cellular clonogenic survival and apoptosis.
Engblom P; Pulkkinen JO; Rantanen V; Hirvonen H; Kulmala J; Grènman R; Grènman S
Eur J Cancer; 1999 Feb; 35(2):284-8. PubMed ID: 10448272
[TBL] [Abstract][Full Text] [Related]
20. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
van Tellingen O; Huizing MT; Panday VR; Schellens JH; Nooijen WJ; Beijnen JH
Br J Cancer; 1999 Sep; 81(2):330-5. PubMed ID: 10496361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
